Understanding research peptides.
A plain-language primer on what peptides are, the chemistry that holds them together, how they are synthesized and purified, and how to store and handle them correctly in the lab. Educational reference only — all materials are supplied strictly for laboratory research use.
What are peptides?
A peptide is a short chain of amino acids — the same building blocks that make up proteins — joined together in a defined sequence. Where a protein may contain hundreds or thousands of amino acids folded into a complex shape, a peptide is smaller and simpler, typically from two up to roughly fifty residues.
Each amino acid contributes a side chain (denoted R), and the specific order of those side chains — the sequence — is what gives a peptide its identity and properties. That sequence is the peptide’s primary structure, and it is the first thing analytical methods confirm.
By convention a peptide is written from its amino terminus (N-terminus) on the left to its carboxyl terminus (C-terminus) on the right, the same direction in which it is synthesized and read.
The boundary between “peptide” and “protein” is one of convention rather than a hard rule. Chains of a few residues are often called oligopeptides; longer chains, polypeptides; and once a chain folds into a stable functional structure it is usually called a protein. What matters analytically is that a peptide has a single, defined sequence that can be confirmed against a known molecular weight.
Sequence is only the first of several levels of organization. The primary structure is the amino-acid order itself. Local folding patterns stabilized by backbone hydrogen bonds — α-helices and β-sheets — make up secondary structure. The overall three-dimensional shape of a single chain is its tertiary structure, and the assembly of multiple chains is quaternary structure. Short research peptides are dominated by primary structure, but even they can adopt transient helical or turn motifs that influence solubility and activity.
Many research peptides are deliberately modified versions of a natural sequence. Common modifications include C-terminal amidation and N-terminal acetylation (which cap the ends and resist enzymatic trimming), cyclization, substitution of non-natural or D-amino acids, and conjugation to a fatty-acid chain or albumin-binding moiety to slow clearance. These changes are why a small sequence edit can dramatically alter stability and duration of action.
The chemistry: peptide bonds.
Amino acids are linked by the peptide bond — an amide bond formed between the carboxyl group (–COOH) of one amino acid and the amino group (–NH₂) of the next. The reaction is a condensation: as the bond forms, a molecule of water is released.
The resulting C(=O)–N–H linkage is planar and relatively rigid, which constrains how the backbone can rotate and underlies the secondary structures (such as helices and sheets) that larger peptides and proteins adopt.
Because each bond is directional, a chain has two distinct ends — a free amino terminus and a free carboxyl terminus — giving every peptide a defined start and finish.
The peptide bond has partial double-bond character: the lone pair on the nitrogen delocalizes into the adjacent carbonyl, so the six atoms of the linkage lie in a plane and rotation about the C–N bond is restricted. Most peptide bonds adopt the lower-energy trans configuration; the exception is bonds preceding proline, which interconvert between cis and trans more readily and can act as conformational switches.
The same bond that holds the chain together is also where it comes apart. Hydrolysis — the reverse of the condensation that formed it — cleaves the amide back into its two fragments, accelerated by heat, extremes of pH, and the proteases and peptidases present in biological fluids. This is why unmodified peptides are typically short-lived, and why duration-extending strategies (terminal capping, D-amino acids, lipidation, albumin binding) target exactly these vulnerable points.
- Amide bond between –COOH and –NH₂
- Condensation reaction — releases H₂O
- Planar, partial-double-bond, usually trans
- Cleaved by hydrolysis and proteases
How peptides are made.
Most research peptides are produced by solid-phase peptide synthesis (SPPS), in which the chain is assembled one residue at a time on an insoluble resin support.
Anchor
The C-terminal amino acid is attached to a solid resin bead, giving a fixed point to build from.
Deprotect & couple
A protecting group is removed and the next amino acid is coupled. The cycle repeats for each residue in the sequence.
Cleave
Once the chain is complete it is cleaved from the resin and side-chain protecting groups are removed.
Purify & characterize
The crude peptide is purified by preparative HPLC, then identity and purity are confirmed by MS and analytical HPLC.
From crude to characterized
Purification removes truncated sequences and reagents left over from synthesis. The purified material is then lyophilized (freeze-dried) to a stable solid for storage and shipping.
Every lot is verified before release: mass spectrometry confirms identity against the expected molecular weight, and reversed-phase HPLC quantifies purity as area percent — the figure reported on the Certificate of Analysis.
The chemistry that makes this routine traces to Bruce Merrifield, whose solid-phase approach earned the 1984 Nobel Prize in Chemistry. Modern SPPS overwhelmingly uses Fmoc protection (base-labile), which replaced the older acid-labile Boc strategy for most work; activated coupling reagents drive each amide-bond formation to near-completion so the cycle can repeat cleanly. Difficult sequences — those prone to on-resin aggregation or containing strings of bulky residues — can lower yield and demand optimized coupling, which is part of why purity, not just identity, is reported per lot. Longer chains beyond the practical reach of stepwise synthesis are instead produced recombinantly or by ligating shorter fragments.
See our testing processPurity by HPLC
Storage & stability.
Handled correctly, lyophilized research peptides are stable for extended periods. Stability depends mostly on temperature, moisture and the number of freeze–thaw cycles after reconstitution.
| Lyophilized, long-term | −20°C (or colder) Sealed, desiccated, protected from light |
|---|---|
| Lyophilized, short-term | 2–8°C for days to weeks Allow vial to reach room temperature before opening |
| After reconstitution | 2–8°C Use within the documented in-use window |
| Reconstitution diluent | Bacteriostatic water; 0.6% acetic acid for low-solubility peptides |
| Freeze–thaw | Minimize cycles Aliquot before freezing to avoid repeated thawing |
| Avoid | Heat, light, humidity and prolonged time at room temperature |
Good practice
Degradation tends to proceed by a few predictable routes, which is why the storage rules look the way they do. Hydrolysis of the backbone is driven by water, heat and pH extremes; oxidation targets methionine, cysteine and tryptophan and is accelerated by light and air; deamidation slowly converts asparagine and glutamine residues; and in solution some sequences aggregate or adsorb to container surfaces. Keeping material cold, dry, dark and frozen as a lyophilized solid suppresses all of these at once — reconstitution starts the clock, which is why an in-use window and aliquoting matter.
- Let sealed vials equilibrate to room temperature before opening to limit condensation.
- Reconstitute gently with the listed diluent using aseptic technique; avoid vigorous shaking.
- Split reconstituted material into single-use aliquots so the full stock isn’t repeatedly frozen and thawed.
- Label aliquots with compound, lot and date, and keep them protected from light.
Stability over time.
The same peptide degrades at very different rates depending on how it’s held. This representative curve tracks the percentage of intact peptide over twelve weeks at three storage temperatures.
Frozen storage keeps material essentially unchanged; refrigerated holds well over the near term; room temperature shows why diluted material shouldn’t be left out. It’s the practical case for the cold chain and for aliquoting.
Representative stability profile for illustration.
Intact peptide remaining
Applications & research.
In the laboratory, characterized peptides serve as reagents and reference materials across a range of in-vitro and analytical research areas.
Receptor & pathway studies
Used in vitro to probe how signaling systems and receptors respond under controlled conditions.
Structure–activity work
Sequence variants and analogs support comparison of how structure relates to measurable activity in assays.
Assay development
Defined, documented material helps establish and validate laboratory assays and protocols.
Analytical reference
High-purity, lot-characterized peptides act as reference standards for HPLC and MS methods.
Method documentation
COA data — purity, method, retention time, identity — supports reproducible, well-documented research.
Quality control
Characterized reagents reduce variability so results reflect the experiment, not the supply.
References & further reading.
Foundational and review literature behind the chemistry on this page, plus a few landmark papers. Links open the original sources.
- Merrifield RB. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. J Am Chem Soc. 1963;85(14):2149–2154. doi
- Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309–325. doi
- Davenport AP, Scully CCG, de Graaf C, et al. Advances in therapeutic peptides targeting G protein-coupled receptors. Nat Rev Drug Discov. 2020;19(6):389–413. doi
- Zheng B, Wang X, Guo M, Tzeng CM. Therapeutic Peptides: Recent Advances in Discovery, Synthesis, and Clinical Translation. Int J Mol Sci. 2025;26(11):5131. doi
- Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly GLP-1 Analogue GLP-SM1. J Med Chem. 2015;58(18):7370–7380. doi
- Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. doi
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly GLP-SM1 in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. doi
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. GLP-2 TRZ Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. doi
For literature on a specific compound, see the Selected research section on its product page, or browse the Publications page.